Singapore is one of the most rapidly ageing societies in the world. Currently, Singapore
ranks first in the world for the incidence of diabetes-induced endstage renal disease (ESRD) …

Objective: In studies of patients with chronic kidney disease (CKD), recommended
nephroprotective therapy with ACE-inhibitors or ARBs has not been shown to reduce …

Abstract Background and Aims In studies of patients with chronic kidney disease (CKD),
recommended nephroprotective therapy with ACE-inhibitors or ARBs has not been shown to …

Aims The overall effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors in patients
with advanced chronic kidney disease (CKD)(estimated glomerular filtration rate (eGFR), 15 …

Although angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
remain the cornerstones to slow kidney disease progression and reduce cardiovascular …

Diabetic kidney disease (DKD) accounts for about half of individuals entering end-stage
renal disease programs. Patients with DKD frequently have associated microvascular …

Chronic kidney disease (CKD) represents an enormous healthcare burden, the
management of which has been stagnant for the last couple of decades, with blockade of the …

Purpose of Review Chronic kidney disease and end-stage kidney disease (ESKD) are well-
established risk factors for cardiovascular disease (CVD), the leading cause of mortality in …

Abstract Background and Aims Renin-angiotensin-system inhibitors (RASi) have been a
foundational therapy in chronic kidney disease (CKD) for several decades. Sodium-glucose …

There is currently an unmet need for effective treatment of chronic kidney disease (CKD) that
slows disease progression, prevents development of end-stage kidney disease and …